[Anti-TNF alpha-induced eruptive nevi: Three cases]

Area of Science:

• Dermatology
• Immunology
• Oncology

Background:

• Eruptive melanocytic nevi (EMN) are characterized by the sudden appearance of multiple nevi.
• EMN has been linked to immunosuppression, certain drugs, and therapies.
• This study investigates EMN in patients undergoing anti-tumor necrosis factor alpha (anti-TNF alpha) treatment.

Observation:

• Three cases of EMN following anti-TNF alpha therapy are presented.
• Case 1: Adalimumab for spondyloarthritis led to nevi on limbs and palm.
• Case 2: Etanercept for spondyloarthritis caused nevi on the trunk.
• Case 3: Infliximab for hidradenitis suppurativa resulted in pigmented lesions on the trunk and palm.

Findings:

• All three patients developed EMN during anti-TNF alpha treatment.
• No transformation to melanoma was observed during follow-up periods ranging from 4 months to 5 years.
• EMN is a rare but documented side effect of anti-TNF alpha therapy.

Implications:

• The occurrence of EMN in patients on anti-TNF alpha therapy necessitates dermatological surveillance.
• Increased risk of cutaneous carcinoma associated with anti-TNF alpha treatment highlights the need for vigilance.
• Patients receiving anti-TNF alpha agents should be advised on sun protection measures.